KENJOCKETY BIOTECHNOLOGY

Kenjockety Biotechnology is developing a new family of bispecific antibodies (BsAbs) to address the significant unmet need of drug resistance in patients with cancer. Our proprietary BASE TM Platform is creating an extensive pipeline of new therapeutics by pairing our foundational antibodies that target Efflux Pumps (EPs) with antibodies to known Tumor Associated Antigen (TAA) targets, to construct BsAbs that more effectively target tumor cells versus normal cells... Kenjockety Biotechnology is creating a new family of multi-modal bispecific antibody (BsAb) therapeutics for patients with drug resistant cancers.

Also known as: Kenjockety Biotechnology, Inc.